Gaffin J M, Raby B A, Petty C R, Hoffman E B, Baccarelli A A, Gold D R, Phipatanakul W
Department of Pediatrics, Division of Respiratory Diseases, Boston Children's Hospital, Boston, MA, USA.
Clin Exp Allergy. 2014;44(5):681-9. doi: 10.1111/cea.12219.
Genetic variation in the β-2 adrenergic receptor gene (ADRB2) has been implicated in asthma severity and control with conflicting results. Epigenetic variation in the ADRB2 may play an important role in asthma phenotype.
We aimed to evaluate whether DNA methylation of ADRB2 is associated with asthma phenotypes in inner-city school-aged children.
Multiple CpG sites in the promoter region of ADRB2 gene were analysed in 177 children enrolled in the School Inner-City Asthma Study. Blood- or saliva-derived DNA was measured by bisulphite-polymerase chain reaction pyrosequencing assay. Average percentage DNA methylation across the sites was evaluated for association with asthma severity (report of dyspnoea, night-time symptoms, rescue medication use, and baseline spirometry) and morbidity (school absences and unscheduled healthcare visits). Three clades composed of highly correlated methylation sites within the methylated segment of ADRB2 were further analysed.
Methylation of individual sites generally ranged from 0% to 6% with average percentage methylation across sites of 2.4%. Univariate analyses strongly favoured the association of higher percentage methylation with lower asthma severity measured by report of dyspnoea. Furthermore, there was a non-significant trend towards less rescue medication use, night-time symptoms, school absences, activity limitation due to asthma, and improved lung function measurements with increased methylation. Multivariate analysis demonstrated methylation of ADRB2 gene significantly associated with less dyspnoea (odds ratio (OR) 0.2, 95% confidence interval (CI), 0.1-0.6, P = 0.002). Each of the three clades of methylation sites showed a strong, but not statistically significant, effect on decreased dyspnoea.
DNA methylation in the ADRB2 gene is associated with decreased asthma symptom severity, suggesting a role for methylation in asthma phenotypes.
β-2肾上腺素能受体基因(ADRB2)的遗传变异与哮喘严重程度及控制情况有关,但结果相互矛盾。ADRB2的表观遗传变异可能在哮喘表型中起重要作用。
我们旨在评估ADRB2的DNA甲基化是否与城市内学龄儿童的哮喘表型相关。
对参加城市内学校哮喘研究的177名儿童的ADRB2基因启动子区域的多个CpG位点进行分析。通过亚硫酸氢盐-聚合酶链反应焦磷酸测序法测量血液或唾液来源的DNA。评估各位点的平均DNA甲基化百分比与哮喘严重程度(呼吸困难报告、夜间症状、急救药物使用情况和基线肺功能测定)及发病率(缺课和非计划医疗就诊)之间的关联。对由ADRB2甲基化片段内高度相关的甲基化位点组成的三个分支进行了进一步分析。
各个位点的甲基化一般在0%至6%之间,各位点的平均甲基化百分比为2.4%。单因素分析强烈支持较高的甲基化百分比与通过呼吸困难报告衡量的较低哮喘严重程度相关。此外,随着甲基化增加,急救药物使用减少、夜间症状减轻、缺课减少、因哮喘导致的活动受限减轻以及肺功能测定改善的趋势虽不显著但存在。多因素分析表明,ADRB2基因的甲基化与较少的呼吸困难显著相关(比值比(OR)为0.2,95%置信区间(CI)为0.1 - 0.6,P = 0.002)。甲基化位点的三个分支中的每一个对减轻呼吸困难均显示出强烈但无统计学意义的作用。
ADRB2基因中的DNA甲基化与哮喘症状严重程度降低相关,表明甲基化在哮喘表型中发挥作用。